Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 7/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17863620 | 0.86 | USP30 (0.54) | DGAT1USP30 | |
| SCHEMBL30233843 | 0.86 | USP30 (0.54) | DGAT1USP30 | |
| SCHEMBL1292021 | 0.82 | USP30 (0.42) | DGAT1USP30LIPGLPL | |
| SCHEMBL10258354 | 0.79 | CNR2 (0.44) | DGAT1USP30GRM5LIPGLPL | |
| SCHEMBL20475499 | 0.78 | DGAT1 (0.38) | DGAT1USP30PDGFRBKDRROCK1 | |
| SCHEMBL21805899 | 0.76 | P2RX7 (0.42) | ROCK1LIPGP4HBLPL | |
| SCHEMBL17419033 | 0.76 | GRM5 (0.40) | DGAT1USP30GRM5 | |
| SCHEMBL26098749 | 0.76 | USP30 (0.40) | DGAT1USP30PDGFRBKDRGRM5 | |
| SCHEMBL29964577 | 0.75 | ALDH1A1 (0.48) | DGAT1USP30 | |
| SCHEMBL1390680 | 0.75 | ALDH1A1 (0.48) | DGAT1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-20200323859-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2020-10-15 | — | — | US | disclosed |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-08-01 | — | — | US | disclosed |
| US-20190142837-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-05-16 | — | — | US | disclosed |
| EP-3472166-A1 | IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-10220036-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2019-03-05 | — | — | US | disclosed |
| EP-3237418-B1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017221100-A1 | IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2017-12-28 | — | — | WO | disclosed |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-12-07 | — | — | US | disclosed |
| EP-3237418-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2017-11-01 | — | — | EP | disclosed |
| US-9580437-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | disclosed |
| WO-2016103155-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | DGAT1 3845/4885USP30 2248/4885PDGFRB 1965/4885 |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | DGAT1 3845/4885USP30 2248/4885PDGFRB 1965/4885 |
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, BMI1 | DGAT1 4729/4885USP30 1417/4885PDGFRB 2779/4885 |
| US-20200323859-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | DGAT1 3845/4885USP30 2248/4885PDGFRB 1965/4885 |
| US-10220036-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | DGAT1 3845/4885USP30 2248/4885PDGFRB 1965/4885 |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | EZH2, DOT1L, BMI1 | DGAT1 4729/4885USP30 1417/4885PDGFRB 2779/4885 |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | DGAT1 3845/4885USP30 2248/4885PDGFRB 1965/4885 |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | DGAT1 3845/4885USP30 2248/4885PDGFRB 1965/4885 |
| US-20190142837-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | DGAT1 3845/4885USP30 2248/4885PDGFRB 1965/4885 |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | DGAT1 3845/4885USP30 2248/4885PDGFRB 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.